and Mentha longifolia by 32% compared to those in control seedlings that did not receive MLE and GE, respectively (Fig
Retrieved 30 July 2022
ABSTRACT Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as game-changers across the cardiovascularkidneymetabolic (CKM) spectrum: overweight/obesity, type 2 diabetes mellitus (T2DM) and associated chronic kidney disease (CKD) and cardiovascular disease (CVD)
The platforms stated current offerings include: Injectable GLP-1s: Compounded semaglutide (injectable), Wegovy, Ozempic, Zepbound, Mounjaro, and generic liraglutide, available for eligible patients depending on state and current supply Following the March 2026 Novo Nordisk deal, access to branded Ozempic is now part of the platform Oral Medication Kits: Personalized oral kits combining medications such as bupropion/naltrexone, metformin, and topiramate, targeting food noise, slow metabolism, and appetite regulation without injections App and Support: 360 care, including nutritional principles, behavioral programs, and custom lessons in the Hims app
